A federal judge in Texas added 23 percent to an already-$482 million judgment against a Johnson & Johnson (NYSE:JNJ) subsidiary, Cordis Corp., in a patent infringement lawsuit over its flagship Cypher drug-eluting stent.
It’s the latest blow to an already beleaguered Johnson & Johnson, which is struggling to manage a string of damaging recalls issued by its medical device and over-the-counter medicine divisions.